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Abstract
The food enzyme considered is a maltogenic amylase (glucan 1,4-a-maltohydrolase; EC 3.2.1.133)
produced with the genetically modified Bacillus subtilis strain NZYM-SM by Novozymes A/S. The food
enzyme contains neither the production organism nor recombinant DNA. The maltogenic amylase is
intended for use in baking processes and starch processing for glucose syrups production. Based on
the maximum use levels recommended for the food processes and individual consumption data from
the EFSA Comprehensive European Food Consumption Database, dietary exposure to the food
enzyme–Total Organic Solids (TOS) was estimated to be up to 0.168 mg TOS/kg body weight (bw) per
day in European populations. The food enzyme did not induce gene mutations in bacteria or
chromosomal aberrations in human lymphocytes. The subchronic toxicity was assessed by means of a
repeated dose 90-day oral toxicity study in rodents. A no observed adverse effect level (NOAEL) was
derived (320 mg TOS/kg bw per day), which, compared with the dietary exposure, results in a
sufficiently high margin of exposure. The allergenicity was evaluated by searching for similarity of the
amino acid sequence to those of known allergens. Three matches to occupational respiratory allergens
were found, however, the Panel considered that there are no indications for food allergic reactions to
the food enzyme. Based on the genetic modifications performed, the manufacturing process, the
compositional and biochemical data provided, the dietary exposure assessment, the findings in the
toxicological studies and allergenicity assessment, the Panel concluded that the food enzyme
maltogenic amylase from Bacillus subtilis strain NZYM-SM does not give rise to safety concerns under
the intended conditions of use.
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1. Introduction
Article 3 of the Regulation (EC) No 1332/20081 provides definitions for ‘food enzyme’ and ‘food
enzyme preparation’.
‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products
thereof including a product obtained by a fermentation process using microorganisms: (i) containing
one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a
technological purpose at any stage of the manufacturing, processing, preparation, treatment,
packaging, transport or storage of foods.
‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which
substances such as food additives and/or other food ingredients are incorporated to facilitate their
storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or
were regulated as processing aids under the legislation of the Member States. On 20 January 2009,
Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes
that are added to food to perform a technological function in the manufacture, processing,
preparation, treatment, packaging, transport or storage of such food, including enzymes used as
processing aids. Regulation (EC) No 1331/2008 established European Union (EU) procedures for the
safety assessment and the authorisation procedure of food additives, food enzymes and food
flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
i) it does not pose a safety concern to the health of the consumer at the level of use proposed;
ii) there is a reasonable technological need;
iii) its use does not mislead the consumer.
All food enzymes currently on the EU market and intended to remain on that market, as well as all
new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority
(EFSA) and an approval via a Union list.
The ‘Guidance on submission of a dossier on a food enzyme for evaluation’ (EFSA, 2009a) lays
down the administrative, technical and toxicological data required.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background as provided by the European Commission
Only food enzymes included in the Union list may be placed on the market as such and used in
foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of
Regulation (EC) No 1332/2008 on food enzymes.
Five applications have been introduced by the companies ‘Novozymes A/S’, ‘AB Enzymes GmbH’.
‘Ajinomoto Europe SAS’ and ‘Nagase (Europa) GmbH’ for the authorisation of the food enzymes Beta-
galactosidase from a genetically modified strain of Bacillus licheniformis (strain NZYM-BT), Mannan
endo-1,4-beta-mannosidase (b-mannanase) from a genetically modified strain of Trichoderma reesei
(strain RF6232), Transglutaminase from Streptoverticillium mobaraense (strain S-8112), Maltogenic
amylase from a genetically modified strain of Bacillus subtilis (strain NZYM-SM) and Glucanase from
Streptomyces violaceoruber (strain pGlu).
Following the requirements of Article 12.1 of Commission Regulation (EU) No 234/20112
implementing Regulation (EC) No 1331/20083, the Commission has verified that the five applications
fall within the scope of the food enzyme Regulation and contains all the elements required under
Chapter II of that Regulation.
1 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/
112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7–15.
2 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European
Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food
flavourings. OJ L 64, 11.3.2011, p. 15–24.
3 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1–6.
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1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority to carry out the safety
assessments on the food enzymes Beta-galactosidase from a genetically modified strain of
Bacillus licheniformis (strain NZYM-BT), Mannan endo-1,4-beta-mannosidase (b-mannanase) from a
genetically modified strain of Trichoderma reesei (strain RF6232), Transglutaminase from
Streptoverticillium mobaraense (strain S-8112), Maltogenic amylase from a genetically modified strain
of Bacillus subtilis (strain NZYM-SM) and Glucanase from Streptomyces violaceoruber (strain pGlu) in
accordance with the article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.
1.2. Interpretation of the Terms of Reference
The present scientific opinion addresses the European Commission request to carry out the safety
assessment of the food enzyme Maltogenic amylase from a genetically modified strain of
Bacillus subtilis (strain NZYM-SM).
1.3. Information on existing authorisations and evaluations
The applicant reports that the Danish and French authorities have evaluated and authorised the
use of the food enzyme from a genetically modified Bacillus subtilis strain NZYM-SM in starch
processing, baking processes and maltose syrup production.
2. Data and methodologies
2.1. Data
The applicant has submitted a dossier supporting the application for authorisation of the food
enzyme maltogenic amylase from a genetically modified strain of B. subtilis (strain NZYM-SM).
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA ‘Guidance on
transparency in the scientific aspects of risk assessment’ (EFSA, 2009b) and following the relevant
existing Guidances from the EFSA Scientific Committee.
The current ‘Guidance on the submission of a dossier for safety evaluation of a food enzyme’ (EFSA
CEF panel, 2009) has been followed for the evaluation of this application with the exception of the
exposure assessment, which was carried out in accordance to the methodology described in the CEF
Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).
3. Assessment
3.1. Technical data
3.1.1. Identity of the food enzyme
IUBMB nomenclature: Glucan 1,4-a-maltohydrolase
Systematic name: 4-a-D-glucan a-maltohydrolase
Synonyms: Maltogenase
IUBMB No: EC 3.2.1.133
CAS No: 160611-47-2.
3.1.2. Chemical parameters
The maltogenic amylase produced with the genetically modified Bacillus subtilis strain NZYM-SM
consists of a single polypeptide of 686 amino acids. The molecular mass, derived from the amino acid
sequence, was calculated to be 75.2 kDa. The sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) gel analysis consistently showed one major protein band in all batches,
migrated slightly below 66 kDa reference protein.
The food enzyme was tested for other enzyme activities, i.e. lipase, protease and glucoamylase,
which were below the limits of quantification (LOQ) of the applied assays, except for one commercial
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batch with a very low amount of glucoamylase activity. No other enzyme activities relevant to the
intended uses were reported by the applicant.
Data on the chemical parameters of the food enzyme were provided for four food enzyme batches,
three batches used for commercialisation and one batch used for the toxicological tests (Table 1). The
average Total Organic Solids (TOS) content of the three food enzyme batches used for
commercialisation was 4.4%; the values ranged from 2.9% to 5.3% (Table 1).
The average enzyme activity/TOS ratio of the three food enzyme batches used for
commercialisation was 330 Maltogenic Amylase Novo Units MANU/mg TOS; the values ranged from
273 to 362 MANU/mg TOS (Table 1). The average activity/TOS ratio of 330 MANU/mg TOS was used
for subsequent calculations.
The food enzyme complies with the specification for lead (not more than 5 mg/kg) as laid down in
the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).
In addition, the levels of arsenic, cadmium and mercury were below the limits of detection of the
employed methodologies.
No antimicrobial activity was detected in any of these batches (FAO/WHO 2006).
The food enzyme complies with the microbiological criteria as laid down in the general
specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which
stipulate that Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms
should not exceed 30 colony forming units (CFU) per gram.
The applicant has provided information on the identity of the antifoam agents used. Taking into
account the nature and properties of the antifoam agents, the manufacturing process and the quality
assurance system implemented by the applicant, the Panel considers their use as of no safety concern.
The Panel considered the compositional data provided for the food enzyme as sufficient.
3.1.3. Properties of the food enzyme
The maltogenic amylase catalyses the hydrolysis of (1?4)-a-D-glucosidic linkages in amylose,
amylopectin and related glucose polymers, liberating maltose units from the non-reducing end of the
polymer chain.
The enzymatic activity is determined on the basis of an in-house method using a maltotriose
standard and expressed in Maltogenic Amylase Novo Units/g (MANU/g). One MANU is defined as the
amount of enzyme that produces 1 lmol glucose per minute using maltotriose as substrate under
the defined assay conditions (reaction conditions: pH = 5.0, T = 37°C, incubation time 30 min). The
enzymatic hydrolysis of maltotriose results in the release of glucose, which is determined quantitatively
using a glucose hexokinase assay.
The food enzyme has been characterised regarding its activity depending on temperature and pH.
The temperature profile of the food enzyme was measured from 40°C to 100°C. The maltogenic
amylase is active at temperatures below 90°C with an optimum between 60°C and 70°C at pH 5.5. The
activity is completely lost after incubation of the enzyme for 30 min at 90°C. The pH optimum is
around pH 5 at 30°C.
Table 1: Compositional data provided for the food enzyme
Parameter Unit
Batch
1 2 3 4(a)
Maltogenic amylase activity MANU/g batch(b) 19,200 10,300 13,400 8,600
Protein % 4.9 2.9 4.7 ND
Ash % 1.0 0.8 1.1 4.8
Water % 93.7 96.3 94.0 86.1
Total organic solids (TOS)(c) % 5.3 2.9 4.9 9.1
Activity/mg TOS MANU/mg TOS 362 355 273 94.5
ND: not determined.
(a): Batch used for the toxicological studies.
(b): MANU: Maltogenic Amylase Novo Units (see Section 3.1.3).
(c): TOS calculated as 100% - % water - % ash.
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3.1.4. Information on the source material
3.1.4.1. Information relating to the genetically modified microorganism
The maltogenic amylase production strain Bacillus subtilis NZYM-SM is deposited in the
with the deposit number
.
3.1.4.2. Characteristics of the parental and recipient microorganism
The parental microorganism is the bacterium B. subtilis, strain (
).
The identity of the parental strain has been confirmed by whole genome sequencing (
). The parental strain has been tested for the absence of cytotoxicity in VERO cells. An
intermediate strain has been tested both in CHO-K1 (Pedersen et al., 2002) and in VERO cells. Both
proved negative.
The recipient strain, B. subtilis , has been developed from the parental strain
3.1.4.3. Characteristics of the donor organisms
3.1.4.4. Description of the genetic modification process
The production strain NZYM-SM was developed from the recipient strain
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3.1.4.5. Safety aspects of the genetic modification
3.1.5. Manufacturing process
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/20044
and in accordance with current Good Manufacturing Practice (GMP).
The food enzyme is produced by a pure culture in a contained, submerged, fed-batch fermentation
system with conventional process controls in place. The identity and purity of the culture are checked
at each transfer step from frozen vials to the end of fermentation.
The food enzyme produced is recovered from the fermentation broth after biomass separation
using filter press filtration. Further purification and concentration involve a series of filtration steps,
including ultrafiltration and sterile filtration.
The food enzyme is then formulated as a liquid or solid product.
The absence of the production microorganism in the food enzyme was demonstrated in
No recombinant DNA was detected in three independent batches in triplicate
The Panel considered the information provided on the raw materials and manufacturing process as
sufficient.
3.1.6. Safety for the environment
The production strain and its recombinant DNA were not detected in the final product. Accordingly,
no environmental risk assessment is required (EFSA GMO Panel, 2011).
3.1.7. Case of need and intended conditions of use
In the original submission, the intended uses of the food enzyme were: starch processing for
glucose syrup production, baking, cereal based and brewing processes. In the course of the
evaluation, the applicant informed EFSA about withdrawal of use of the food enzyme in cereal based
and brewing processes.
The intended uses and the recommended use levels are summarised in Table 2.
4 Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives.
OJ L 226, 25.6.2004, p. 3–21.
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In baking processes, the food enzyme is added during the preparation of the dough. It is used to
hydrolyse starch and related polysaccharides to delay the staling process.
In starch processing for glucose syrups production, the food enzyme is added during the
saccharification step. It is used to degrade starch polysaccharides into maltose and glucose in an
efficient way.
3.1.8. Reaction and fate in food
The maltogenic amylase catalyses the hydrolysis of (1?4)-a-D-glucosidic linkages in amylose,
amylopectin and related glucose polymers, liberating maltose units from the non-reducing end of the
polymer chain.
Experimental data on the removal (> 99%) of protein in the course of starch processing for glucose
syrups production have been provided (Documentation provided to EFSA No 3). The Panel considered
the evidence as sufficient to conclude that residual amounts of TOS are removed by the purification
steps applied during the production of glucose syrups, i.e. filtration, ion exchange chromatography,
carbon treatment, crystallisation.
The data and information provided indicate that the maltogenic amylase is inactivated during the
baking processes under the intended conditions of use.
3.2. Dietary exposure
Exposure estimates were calculated using the methodology described in the CEF Panel statement
on the exposure assessment of food enzymes (EFSA CEF Panel, 2016). The assessment of the food
process covered in this opinion involved selection of relevant food groups and application of process
and technical conversion factors (Appendix B). These input data were subject to a stakeholder
consultation through open calls,5 and adjusted in accordance with feedback received.
3.2.1. EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (hereafter the EFSA
Comprehensive Database6) has been populated with detailed national data on food consumption.
Competent authorities in European countries provide EFSA with data regarding the level of food
consumption by individual consumers, as taken from the most recent national dietary survey in their
country (EFSA, 2011a).
The food consumption data gathered by EFSA were collected using different methodologies and
thus direct country-to-country comparisons should be made with caution. Depending on the food
category and the level of detail used in exposure calculations, uncertainties might be introduced owing
to subjects possibly underreporting and/or misreporting of consumption amounts. Nevertheless, the
EFSA Comprehensive Database is the best available source of food consumption data across Europe.
Food consumption data from the population groups: infants, toddlers, children, adolescents, adults
and the elderly were used for the exposure assessment. For the present assessment, food





Recommended dosage of the food enzyme
Baking processes(b) Flour Up to 5,000 MANU/kg flour corresponding to 15 mg
TOS/kg flour
Starch processing for glucose syrups
production
Starch Up to 16,500 MANU/kg starch corresponding to 49.5 mg
TOS/kg starch
MANU: Maltogenic Amylase Novo Units; TOS: Total Organic Solids.
(a): The description provided by the applicant has been harmonised by EFSA according to the ‘EC working document describing
the food processes in which food enzymes are intended to be used’ – not yet published at the time of adoption of this
opinion.
(b): Restricted to bread-making including buns, scones and brioches.
5 http://www.efsa.europa.eu/en/data/call/161110
6 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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consumption data were available from 33 different dietary surveys carried out in 19 European
countries (Appendix A).
Consumption records were codified according to the FoodEx classification system (EFSA, 2011b).
3.2.2. Exposure assessment methodology
Chronic exposure was calculated based on individual consumption, averaged over the total survey
period, excluding surveys with only one day per subject. High-level exposure/intake was calculated for
only those population groups, in which the sample size was sufficiently large to allow calculation of the
95th percentile (EFSA, 2011a).
The exposure per FoodEx category was subsequently added to derive an individual total exposure
per day. Finally, these exposure estimates were averaged over the number of survey days and
normalised for individual body weight (bw), resulting in an individual average exposure/day per kg bw
for the survey period. This was done for all individuals in the survey and per age class, resulting in
distributions of individual average exposure per survey and age class. Based on these distributions, the
mean and 95th percentile exposures were calculated per survey for the total population and per age
class.
3.2.3. Exposure to food enzyme–TOS according to the intended use proposed by
the applicant
Exposure to the food enzyme–TOS was based on intended uses and the recommended maximum
use levels of the food enzyme–TOS provided by the applicant (Table 2). Foods/ingredients derived
through starch processing, i.e. glucose syrups, were excluded from the analysis, as the
Panel considered the presence of residual amounts of TOS in glucose syrups as negligible (see
Section 3.1.7). Therefore, food enzyme–TOS exposure was calculated from foods produced involving a
baking process only. The applicant proposed a restricted number of baking processes (Table 2),
however, the Panel decided to follow the exposure methodology described in Section 3.2, i.e. inclusion
of all baking applications, since no need for refining the exposure was identified.
Relevant food groups and/or individual foods were selected from the Comprehensive Database and
were assumed to always contain the food enzyme–TOS at the maximum recommended use level. This
will result in an overestimation of exposure to food enzyme–TOS.
To facilitate matching of the reported use levels for baking process with foods identified in the
Comprehensive Database, the selected foods were disaggregated to ingredient level as appropriate,
and converted into the corresponding raw material, i.e. flour, via the application of conversion factors
(Appendix B). For example, consumption of 100 g of bread was converted into an intake of 70 g flour
(recipe fraction of 0.7) and then multiplied by 15.0 mg TOS/kg flour, as provided by the applicant, to
arrive at an exposure of 1.05 mg TOS.
Exposure to the food enzyme–TOS was calculated by multiplying values reported for each food
category by their respective consumption amount per kilogram of body weight (kg bw) separately for
each individual in the database. Table 3 provides an overview of the derived exposure estimates. The
average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey are
reported in Appendix C – Table 1. The contribution of the food enzyme–TOS from each FoodEx
category to the total dietary exposure is indicated in Appendix C – Table 2.
Table 3: Summary of estimated dietary exposure to food enzyme–TOS in six population groups
Population group
Estimated exposure (mg/kg bw per day)
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3.2.4. Uncertainty analysis
In accordance with the guidance provided in the EFSA Opinion related to uncertainties in dietary
exposure assessment (EFSA, 2006), the following sources of uncertainties have been considered and
are summarised in Table 4.
The conservative approach applied to the exposure estimate to food enzyme–TOS, in particular,
assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led
to a considerable overestimation of the exposure.
3.3. Toxicological data
The batch used for toxicological testing is an enzyme concentrate without addition of additives or
other standardisation or stabilisation ingredients. It has been produced in accordance with the
methods used for commercial batches, but the concentration has been done by means of evaporation
instead of by ultrafiltration. The evaporation step removes water and thereby relatively increases non-
enzymatic organic matter compared to activity. Table 1 shows that the food enzyme batch 4 used for
the toxicological assays has the lowest specific activity (enzyme activity/mg TOS), which indicates that
it is less pure than the commercial batches and thus can be considered as a ‘worst-case’ situation.
Consequently, on the basis of the data provided, batch 4 is considered cruder than the three batches
for commercialisation and its use for toxicological testing is considered acceptable.
3.3.1. Genotoxicity
3.3.1.1. Bacterial reverse mutation test
To investigate the potential of the maltogenic amylase to induce gene mutations in bacteria, a
bacterial reverse mutation assay (Ames test) was performed according to OECD Test Guideline 471
(OECD, 1997a) and following Good Laboratory Practice (GLP). Four strains of Salmonella Typhimurium
(TA1535, TA100, TA1537 and TA98) and Escherichia coli WP2uvrA were used in the presence or
absence of metabolic activation with S9-mix, applying the direct plate incorporation method. Two
separate experiments were carried out using six different concentrations (0, 156, 313, 625, 1,250,
2,500 and 5,000 lg dry matter/plate) of the food enzyme, appropriate positive control chemicals and
deionised water as a negative control. The concentrations tested corresponded to ca. 0, 102, 205,






Consumption data: different methodologies/representativeness/underreporting/
misreporting/no portion size standard
+/
Use of data from food consumption survey of a few days to estimate long-term
(chronic) exposure for high percentiles (95th percentile)
+
Possible national differences in categorisation and classification of food +/
Model assumptions and factors
The estimation considered all food groups involving baking processes (e.g. breads
and cakes)
+
FoodEx categories included in the exposure assessment were assumed to always
contain the food enzyme–TOS
+
Exposure to food enzyme–TOS was always calculated based on the recommended
maximum use level
+
Selection of broad FoodEx categories for the exposure assessment +
Use of recipe fractions in disaggregation FoodEx categories likely to contain the food
enzyme
+/
Use of technical factors in the exposure model +/
+: uncertainty with potential to cause overestimation of exposure; : uncertainty with potential to cause underestimation of
exposure.
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409, 818, 1,637 and 3,273 lg TOS/plate. All positive controls induced significant increases in revertant
colony numbers, confirming the sensitivity of the tests and the efficacy of the S9-mix. Upon treatment
with the food enzyme, bacteriotoxic effects were not observed in this study. Small non-reproducible
increases in the number of colonies without dose relation were observed in few test series with S9
mix. These increases were not considered toxicologically relevant. Upon treatment with the food
enzyme, there was no evidence of mutagenic activity of the food enzyme in this mutation test.
The Panel concluded that the food enzyme maltogenic amylase did not induce gene mutations in
the bacterial reverse mutation assay under the test conditions employed in this study.
3.3.1.2. In vitro mammalian chromosomal aberration test
The in vitro chromosome aberration test was carried out according to the OECD Test Guideline 473
(OECD, 1997b) and following GLP. Cultures of peripheral blood human lymphocytes were prepared
from the pooled blood of three female donors. The lymphocytes, proliferation of which was stimulated
with phytohaemagglutinin (PHA), were treated with the food enzyme, sterile water (negative control)
or appropriate positive controls in the absence or the presence of the S9-mix. Two experiments were
performed. In the first experiment, applying 3 + 17 h treatment, the cultures were exposed to the
food enzyme at concentrations of 3,200, 4,000 and 5,000 lg food enzyme/mL (corresponding to ca
291, 364 and 455 lg TOS/mL) in the presence and absence of the S9-mix. In the second experiment,
applying continuous 20 + 0 h treatment without metabolic activation, concentrations scored for the
chromosome aberrations were 1,886, 2,219 and 3,071 lg food enzyme/mL (corresponding to ca 172,
202 and 279 lg TOS/mL). For the short-term treatment (3 + 17 h) with metabolic activation,
concentrations of 3,613, 4,250 and 5,000 lg food enzyme/mL (corresponding to 329, 387 and 455 lg
TOS/mL) were tested. Reductions in the mitotic index of 47% and 1% were observed at 3,071 and
5,000 lg food enzyme/mL in the long-term treatment without S9-mix and the second short-term
treatment in the presence of the S9-mix, respectively. Only cells with 44–46 chromosomes were
analysed for chromosome aberrations, polyploidy and endoreduplication. Two hundred metaphases
were analysed at each concentration. For all food enzyme concentrations used, the frequency of cells
with chromosomal aberrations was similar to that of negative controls (values of p ≤ 0.05 were
considered as significant), except for 4,250 lg of food enzyme/mL in the second experiment in pulse
3 + 17 h treatment in the presence of S9-mix. As this effect was not reproducible, not concentration
related, and found in one culture only, it is not considered to be of biological relevance.
The Panel concluded that the food enzyme maltogenic amylase did not induce chromosome
aberrations, polyploidy and or endoreduplication in cultured human peripheral blood lymphocytes when
tested under the test conditions employed in this study.
3.3.2. Repeated dose 90-day oral toxicity study in rodents
A repeated dose 90-day oral toxicity study was performed in accordance with OECD Test Guideline
408 (OECD, 1998) and following GLP. Groups of 10 male and 10 female Sprague–Dawley rats received
the food enzyme orally via gavage volume of 10 mL/kg bw per day, corresponding to 97, 320 or
968 mg TOS/kg bw per day (referred to as low, mid and high dose groups). The control group
received the vehicle water.
Food consumption of treated females was sporadically higher than that of the control animals and
total food consumption of the low- and mid-dose females was significantly higher than that of the
controls. This was reflected in a tendency for mean body weights of all treated females to be higher
than that of the control animals from approximately day 15 but these differences seemed to be due
partly to the marked contribution of individual animals to the mean group values. There was no
dosage-related response, and group mean body weight gain of the food enzyme groups was within
15% of the control value. Although the food consumption of all treated males tended to be below that
of the control group and significantly in the last 2 weeks of dosage, no significant difference was seen
either between the tested groups or in the weight gain of the animals. The differences in food
consumption were considered not to be toxicologically relevant.
At termination of the study, the relative neutrophil count (% of white blood cells) of high-dose
males and females and the absolute neutrophil count of high-dose males and mid-dose females were
significantly higher than those of the control groups. Relative, but not absolute lymphocytes were
decreased and relative, but not absolute monocytes were significantly increased in high-dose males.
No dose dependency was observed and values were within historical controls. Fibrinogen was
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marginally increased in all treated females but there was no effect on clotting time. The
haematological changes were not considered of toxicological importance.
A few statistically significant differences in clinical chemistry parameters were seen between the
control group and the treated groups. The effects included increased urea and phosphorus in high-
dose males, increased AST in high-dose females and increased beta protein in all treated females, but
without a clear dose–response relationship.
Significant differences were seen between the control groups and the treated groups in urinalysis.
The effects were increased epithelial cells in low- and high-dose males, increased N-acetyl-b-D-
glucosaminidase (NAG)/mmol creatinine in high-dose females, increased leucocytes and epithelial cells
in mid-dose females. The relative kidney weight of high-dose males and the absolute kidney weight of
high-dose females were significantly higher than those of the control groups. Although no
histopathological findings were observed at necropsy, the Panel decided as a conservative approach to
select the mid-dose of 320 mg TOS/kg bw per day as the NOAEL of this study, since at the higher
dose, statistically significant changes were observed in several kidney relevant parameter, among
which NAG, which is an indicator or kidney damage.
A comparison of the NOAEL (320 mg TOS/kg bw per day) from the 90-day study with the derived
exposure estimates in six human population groups of 0.010–0.095 mg TOS/kg bw per day at the
mean and from 0.032 to 0.168 mg TOS/kg bw per day at the 95th percentile, resulted in margins of
exposures (MOEs) above 1,905, indicating that there is no toxicological concern.
3.4. Allergenicity
The allergenicity assessment considers only the food enzyme and not any carrier or other excipient
which may be used in the final formulation.
The allergenicity of maltogenic amylase produced with the genetically modified Bacillus
subtilis strain NZYM-SM was assessed by comparing its amino acid sequence with those of known
allergens according to the EFSA Scientific opinion on the assessment of allergenicity of GM plants and
microorganisms and derived food and feed of the Scientific Panel on Genetically Modified
Organisms (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino
acids as criterion, three matches were found. The matching allergens are: Asp o 21, an a-amylase
produced by Aspergillus oryzae; Asp f 13, a serine protease produced by Aspergillus fumigatus; and
Sch c 1, a glucoamylase produced by Schizophyllum commune.
a-Amylase from A. oryzae (Brisman and Belin, 1991; Brisman, 2002), serine protease from
A. fumigatus (Kurup et al., 2002) and glucoamylase from Schizophyllum commune (Sander et al.,
1998; Quirce et al., 2002) are all described as occupational respiratory allergens associated with
baker’s asthma. However, several studies have shown that adults with occupational asthma to a food
enzyme (like a-amylase) can commonly ingest the corresponding enzyme without acquiring clinical
symptoms of food allergy (Cullinan et al., 1997; Brisman, 2002; Poulsen, 2004; Armentia et al., 2009).
Taking into account the wide use of a-amylase, only a low number of case reports have been
described in literature focussed on allergic reactions upon oral exposure to a-amylase in individuals
respiratory sensitised to a-amylase (Baur and Czuppon, 1995; Kanny and Moneret-Vautrin, 1995;
Moreno-Ancillo et al., 2004). In addition, such information is not reported for serine protease and
glucoamylase. Therefore, it can be concluded that an allergic reaction upon oral ingestion of
maltogenic amylase, produced by the genetically modified B. subtilis strain NZYM-SM, in individuals
respiratory sensitised to a-amylase, serine protease produced by A. fumigatus or glucoamylase
produced by Schizophyllum commune cannot be excluded, but the likelihood is considered to be low.
Moreover, no information is available on oral sensitisation or elicitation reactions of this maltogenic
amylase.
Bindslev-Jensen et al. (2006) investigated the cross reactivity of 19 different commercial enzymes
used in the food industry in allergic patients (400 patients allergic to inhalation allergens, food
allergens, allergens of bee or wasp or drugs). A maltogenic amylase from a B. subtilis species only
gave a positive skin prick test in two allergic patients. Nevertheless, it was further tested by ingestion
(DBPCFC) and was found to be negative to both active and placebo.
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According to the information provided, substances or products that may cause allergies (
) or intolerances (Regulation EU 1169/2011)7 are used as raw materials in the media fed to the
microorganisms. However, these substances will be degraded and utilised by the microorganisms for
cell growth, cell maintenance and production of enzyme. In addition, the microbial biomass and
fermentation solids will be removed. Therefore, potentially allergenic residues of these foods employed
as protein sources are not expected to be present.
Taken together, the Panel considers that there are no indications for allergic reactions by dietary
exposure to the food enzyme maltogenic amylase produced with the genetically modified
B. subtilis strain NZYM-SM.
Conclusions
Based on the genetic modifications performed, the manufacturing process, the compositional and
biochemical data provided, the dietary exposure assessment and the findings in the toxicological
studies and the allergenicity assessment, the Panel concluded that the food enzyme maltogenic
amylase from Bacillus subtilis strain NZYM-SM does not give rise to safety concerns under the intended
conditions of use.
Recommendations
Documentation provided to EFSA
1) Dossier ‘Maltogenic amylase produced by a genetically modified strain of Bacillus subtilis
(strain NZYM-SM)’. February 2015. Submitted by Novozymes A/S.
2) Summary report on genotoxicity and subchronic toxicity study related to maltogenic alpha-
amylase produced with a strain of Bacillus subtilis (strain NZYM-SM). March 2016. Delivered
by FoBiG GmbH, Freiburg (Germany).
3) Additional information on ‘Food enzyme carry/over in glucose syrups’. February 2017.
Provided by the Association of Manufacturers and Formulators of Enzyme Products.
4) Additional information was received from Novozymes A/S in November 2017.
5) Additional information was received from Novozymes A/S in January 2018.
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bw body weight
CAS Chemical Abstracts Service
CFU colony forming units
DBPCFC double blind, placebo controlled food challenge
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EC Enzyme Commission
EINECS European Inventory of Existing Commercial Chemical Substances
FAO Food and Agricultural Organization
GLP Good Laboratory Practice
GMO genetically modified organism
GMP Good Manufacturing Practice
IUBMB International Union of Biochemistry and Molecular Biology
JECFA Joint FAO/WHO Expert Committee on Food Additives
LOD limit of detection
LOQ limit of quantification
MOE margin of exposure
NAG N-acetyl-b-D-glucosaminidase
NOAEL no observed adverse effect level
OECD Organisation for Economic Cooperation and Development
PCR polymerase chain reaction
PHA phytohaemagglutinin
SDS–PAGE sodium dodecyl sulfate–poly acrylamide gel electrophoresis
TOS Total Organic Solids
WHO World Health Organization
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Appendix A – Population groups considered for the exposure assessment
Population Age range
Countries with food consumption surveys covering more
than one day
Infants From 12 weeks on up to and
including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, United Kingdom
Toddlers From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, United Kingdom
Children(a) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland,
France, Germany, Greece, Italy, Latvia, Netherlands, Spain,
Sweden, United Kingdom
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Spain, Sweden, United Kingdom
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, United Kingdom
The elderly(a) From 65 years of age and
older
Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Romania, Sweden, United Kingdom
(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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Appendix B – FoodEx categories used to derive exposure estimates for the
food enzyme–TOS and the respective conversion factors









A.01 Grains and grain-based products
(unspecified)
0.8 1 15.0
A.01.03 Grain milling products (unspecified) 1 1 15.0
A.01.03.001 Wheat milling products (unspecified) 1 1 15.0
A.01.03.001.001 Wheat flour, brown 1 1 15.0
A.01.03.001.002 Wheat flour, Durum 1 1 15.0
A.01.03.001.003 Wheat flour, white 1 1 15.0
A.01.03.001.004 Wheat flour, wholemeal 1 1 15.0
A.01.03.001.005 Graham flour 1 1 15.0
A.01.03.001.006 Wheat flour, gluten free 1 1 15.0
A.01.03.001.014 Wheat starch 1.2 1 15.0
A.01.03.002 Rye milling products (unspecified) 1 1 15.0
A.01.03.002.001 Rye flour, gluten free 1 1 15.0
A.01.03.002.002 Rye flour, light 1 1 15.0
A.01.03.002.003 Rye flour, medium 1 1 15.0
A.01.03.002.004 Rye flour, wholemeal 1 1 15.0
A.01.03.003 Buckwheat milling products (unspecified) 1 1 15.0
A.01.03.003.001 Buckwheat flour 1 1 15.0
A.01.03.004 Corn milling products (unspecified) 1 1 15.0
A.01.03.004.001 Corn flour 1 1 15.0
A.01.03.004.003 Corn starch 1.3 1 15.0
A.01.03.005 Oat milling products (unspecified) 1 1 15.0
A.01.03.005.002 Oat flour 1 1 15.0
A.01.03.005.004 Oat starch 1.2 1 15.0
A.01.03.006 Rice milling products (unspecified) 1 1 15.0
A.01.03.006.001 Rice flour 1 1 15.0
A.01.03.006.002 Rice flour white 1 1 15.0
A.01.03.006.003 Rice flour, instant 1 1 15.0
A.01.03.006.004 Rice starch 1.2 1 15.0
A.01.03.007 Spelt milling products 1 1 15.0
A.01.03.008 Other milling products (unspecified) 1 1 15.0
A.01.03.008.001 Amaranth flour 1 1 15.0
A.01.03.008.002 Barley flour 1 1 15.0
A.01.03.008.003 Chapatti flour 1 1 15.0
A.01.03.008.004 Flour mix, wheat/rye/barley/oats 1 1 15.0
A.01.03.008.005 Millet flour 1 1 15.0
A.01.03.008.007 Sorghum flour 1 1 15.0
A.01.04 Bread and rolls (unspecified) 1 0.7 15.0
A.01.04.001 Wheat bread and rolls 1 0.7 15.0
A.01.04.002 Rye bread and rolls 1 0.7 15.0
A.01.04.003 Mixed wheat and rye bread and rolls 1 0.7 15.0
A.01.04.004 Multigrain bread and rolls 1 0.7 15.0
A.01.04.005 Unleavened bread, crisp bread and rusk
(unspecified)
1 0.8 15.0
A.01.04.005.001 Crisp bread, rye wholemeal 1 0.9 15.0
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A.01.04.005.002 Crisp bread, rye, light 1 0.9 15.0
A.01.04.005.003 Crisp bread, wheat, wholemeal 1 0.9 15.0
A.01.04.005.004 Crisp bread, wheat, light 1 0.9 15.0
A.01.04.005.005 Rusk, light 1 0.9 15.0
A.01.04.005.006 Rusk, wholemeal 1 0.9 15.0
A.01.04.005.007 Pita bread 1 0.7 15.0
A.01.04.005.008 Matzo 1 0.9 15.0
A.01.04.005.009 Tortilla 1 0.7 15.0
A.01.04.006 Other bread 1 0.7 15.0
A.01.04.007 Bread products 1 0.7 15.0
A.01.07 Fine bakery wares (unspecified) 1 0.5 15.0
A.01.07.001 Pastries and cakes (unspecified) 1 0.5 15.0
A.01.07.001.001 Beignets 1 0.15 15.0
A.01.07.001.002 Buns 1 0.7 15.0
A.01.07.001.003 Cake from batter 1 0.25 15.0
A.01.07.001.004 Cheese cream cake 1 0.24 15.0
A.01.07.001.005 Cheese cream sponge cake 1 0.24 15.0
A.01.07.001.006 Chocolate cake 1 0.24 15.0
A.01.07.001.007 Chocolate cake with fruits 1 0.24 15.0
A.01.07.001.008 Cream cake 1 0.24 15.0
A.01.07.001.009 Cream cheese cake 1 0.24 15.0
A.01.07.001.010 Cream custard cake 1 0.24 15.0
A.01.07.001.011 Cream custard sponge cake 1 0.24 15.0
A.01.07.001.012 Croissant 1 0.5 15.0
A.01.07.001.013 Croissant, filled with chocolate 1 0.5 15.0
A.01.07.001.014 Croissant, filled with cream 1 0.5 15.0
A.01.07.001.015 Croissant, filled with jam 1 0.5 15.0
A.01.07.001.016 Croquembouche 1 0.15 15.0
A.01.07.001.017 Doughnuts 1 0.24 15.0
A.01.07.001.018 Clair 1 0.15 15.0
A.01.07.001.019 Flan 1 0.5 15.0
A.01.07.001.020 Fruit cake 1 0.6 15.0
A.01.07.001.021 Fruit pie 1 0.15 15.0
A.01.07.001.022 Cheese pie 1 0.15 15.0
A.01.07.001.023 Fruit tart 1 0.15 15.0
A.01.07.001.024 Gingerbread 1 0.6 15.0
A.01.07.001.025 Gougere 1 0.15 15.0
A.01.07.001.026 Kringles 1 0.25 15.0
A.01.07.001.027 Nut cream cake 1 0.24 15.0
A.01.07.001.028 Pancakes 1 0.25 15.0
A.01.07.001.029 Profiterole 1 0.15 15.0
A.01.07.001.030 Pyramid cake 1 0.25 15.0
A.01.07.001.031 Rhubarb flan 1 0.15 15.0
A.01.07.001.032 Scone 1 0.5 15.0
A.01.07.001.033 Sponge dough 1 0.25 15.0
A.01.07.001.034 Sponge cake 1 0.25 15.0
A.01.07.001.035 Sponge cake roll 1 0.25 15.0
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A.01.07.001.036 Muffins 1 0.25 15.0
A.01.07.001.037 Waffles 1 0.25 15.0
A.01.07.001.038 Apple strudel 1 0.15 15.0
A.01.07.001.039 Cream-cheese strudel 1 0.24 15.0
A.01.07.001.040 Cheese pastry goods from puff pastry 1 0.15 15.0
A.01.07.001.041 Croissant from puff pastry 1 0.6 15.0
A.01.07.001.042 Brioche 1 0.5 15.0
A.01.07.001.044 Lebkuchen 1 0.6 15.0
A.01.07.001.045 Dumpling 1 0.5 15.0
A.01.07.001.046 Cake marbled, with chocolate 1 0.5 15.0
A.01.07.001.047 Marzipan pie 1 0.25 15.0
A.01.07.001.048 Baklava 1 0.15 15.0
A.01.07.002 Biscuits (cookies) 1 0.9 15.0
A.01.07.002.001 Biscuits, sweet, plain 1 0.9 15.0
A.01.07.002.002 Biscuits, chocolate filling 1 0.81 15.0
A.01.07.002.003 Biscuits, cream filling 1 0.81 15.0
A.01.07.002.004 Biscuits, fruit filling 1 0.81 15.0
A.01.07.002.005 Biscuits, vanilla filling 1 0.81 15.0
A.01.07.002.006 Butter biscuits 1 0.81 15.0
A.01.07.002.007 Biscuit, iced 1 0.81 15.0
A.01.07.002.008 Speculaas 1 0.9 15.0
A.01.07.002.009 Biscuits, sweet, wheat wholemeal 1 0.9 15.0
A.01.07.002.010 Biscuits, oat meal 1 0.9 15.0
A.01.07.002.011 Biscuits, spelt meal 1 0.9 15.0
A.01.07.002.012 Biscuits, salty 1 0.9 15.0
A.01.07.002.013 Biscuits, salty, with cheese 1 0.81 15.0
A.01.07.002.014 Sticks, salty 1 0.81 15.0
A.17.03.003 Biscuits, rusks and cookies for children 1 0.9 15.0
A.18.04.001 Find bakery products for diabetics 1 0.5 15.0
A.19.01.001 Sandwich and sandwich-like meal 1 0.32 15.0
A.19.01.002 Pizza and pizza-like pies 1 0.3 15.0
TOS: Total Organic Solids.
(a): Available at see http://www.fao.org/fileadmin/templates/ess/documents/methodology/tcf.pdf
(b): Derived from publically available recipe information, and/or food label information (such as the Mintel’s Global New Products
Database http://www.mintel.com/global-new-products-database).
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Appendix C – Dietary exposure estimates to the food enzyme–TOS in
details
Information provided in this appendix is shown in an excel file (downloadable http://onlinelibrary.
wiley.com/wol1/doi/10.2903/j.efsa.2018.5171/suppinfo).
The file contains two sheets, corresponding to two tables.
Table 1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country and
survey.
Table 2: The contribution of the food enzyme–TOS from each FoodEx category to the total dietary
exposure.
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